{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T14:45:21Z","timestamp":1790779521252,"version":"4.1.0"},"reference-count":129,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2021,5,31]],"date-time":"2021-05-31T00:00:00Z","timestamp":1622419200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Molecules"],"abstract":"<jats:p>The unique electron deficiency and coordination property of boron led to a wide range of applications in chemistry, energy research, materials science and the life sciences. The use of boron-containing compounds as pharmaceutical agents has a long history, and recent developments have produced encouraging strides. Boron agents have been used for both radiotherapy and chemotherapy. In radiotherapy, boron neutron capture therapy (BNCT) has been investigated to treat various types of tumors, such as glioblastoma multiforme (GBM) of brain, head and neck tumors, etc. Boron agents playing essential roles in such treatments and other well-established areas have been discussed elsewhere. Organoboron compounds used to treat various diseases besides tumor treatments through BNCT technology have also marked an important milestone. Following the clinical introduction of bortezomib as an anti-cancer agent, benzoxaborole drugs, tavaborole and crisaborole, have been approved for clinical use in the treatments of onychomycosis and atopic dermatitis. Some heterocyclic organoboron compounds represent potentially promising candidates for anti-infective drugs. This review highlights the clinical applications and perspectives of organoboron compounds with the natural boron atoms in disease treatments without neutron irradiation. The main topic focuses on the therapeutic applications of organoboron compounds in the diseases of tuberculosis and antifungal activity, malaria, neglected tropical diseases and cryptosporidiosis and toxoplasmosis.<\/jats:p>","DOI":"10.3390\/molecules26113309","type":"journal-article","created":{"date-parts":[[2021,5,31]],"date-time":"2021-05-31T21:42:06Z","timestamp":1622497326000},"page":"3309","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":55,"title":["Organoboron Compounds: Effective Antibacterial and Antiparasitic Agents"],"prefix":"10.3390","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0015-1453","authenticated-orcid":false,"given":"Paolo Saul","family":"Coghi","sequence":"first","affiliation":[{"name":"School  of Pharmacy Macau, University of Science and Technology, Taipa Macau 999078, China"},{"name":"State Key Laboratory of Quality Research in Chinese Medicine, Macau University of Science and Technology, Taipa Macau 999078, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinghuai","family":"Zhu","sequence":"additional","affiliation":[{"name":"The State Key Laboratory of Anti-Infective Drug Development (NO. 2015DQ780357), Sunshine Lake Pharma Co., Ltd., Dongguan 523871, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongming","family":"Xie","sequence":"additional","affiliation":[{"name":"The State Key Laboratory of Anti-Infective Drug Development (NO. 2015DQ780357), Sunshine Lake Pharma Co., Ltd., Dongguan 523871, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Narayan S.","family":"Hosmane","sequence":"additional","affiliation":[{"name":"Department of Chemistry and Biochemistry, Northern Illinois University, DeKalb, IL 60115, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingjun","family":"Zhang","sequence":"additional","affiliation":[{"name":"The State Key Laboratory of Anti-Infective Drug Development (NO. 2015DQ780357), Sunshine Lake Pharma Co., Ltd., Dongguan 523871, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,5,31]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1021\/acs.chemrev.7b00602","article-title":"Hit Generation in TB Drug Discovery: From Genome to Granuloma","volume":"118","author":"Yuan","year":"2018","journal-title":"Chem. Rev."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"3805","DOI":"10.1038\/s41467-018-05777-2","article-title":"A high throughtput screen for next-generation leads targeting malaria parasite transmission","volume":"9","author":"Delves","year":"2018","journal-title":"Nat. Commun."},{"key":"ref_3","unstructured":"World Health Organization (WHO) (2021, January 10). Why Are Some Tropical Diseases Called \u201cNeglected\u201d?. Available online: http:\/\/www.who.int\/features\/qa\/58\/en\/."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Hotez, P.J., Aksoy, S., Brindley, P.J., and Kamhawi, S. (2020). What constitutes a neglected tropical disease?. PLoS Negl. Trop. Dis., 14.","DOI":"10.1371\/journal.pntd.0008001"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"e72788","DOI":"10.1371\/journal.pone.0072788","article-title":"Global causes of diarrheal disease mortality in children <5 years of age: A systematic review","volume":"8","author":"Lanata","year":"2013","journal-title":"PLoS ONE"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"653","DOI":"10.4155\/fmc.13.38","article-title":"Boron chemicals in diagnosis, therapeutics","volume":"5","author":"Das","year":"2013","journal-title":"Future Med. Chem."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"12930","DOI":"10.1021\/jp208796b","article-title":"Topological principles of borosilicate glass chemistry","volume":"115","author":"Smedskjaer","year":"2011","journal-title":"J. Phys. Chem. B."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Hosmane, N.S., Maguire, J.A., Zhu, Y., and Takagaki, M. (2012). Boron and Gadolinium Neutron Capture Therapy for Cancer Treatment, World Scientific Publishing Co. Pte. Ltd.","DOI":"10.1142\/9789814338684"},{"key":"ref_9","first-page":"488","article-title":"Borax, boric acid, boron\u2014From exotic to commodity","volume":"12","author":"Wisniak","year":"2005","journal-title":"Indian J. Chem. Technol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"5019","DOI":"10.2174\/0929867325666180904105212","article-title":"The current status and perspectives of delivery strategy for boronbased drugs","volume":"26","author":"Zhu","year":"2019","journal-title":"Curr. Med. Chem."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"7035","DOI":"10.1021\/cr200038x","article-title":"Carbaboranes as pharmacophores: Properties, synthesis, application strategies","volume":"111","author":"Scholz","year":"2011","journal-title":"Chem. Rev."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"4279","DOI":"10.1039\/c0cs00131g","article-title":"Boron-containing inhibitors of synthetases","volume":"40","author":"Baker","year":"2011","journal-title":"Chem. Soc. Rev."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.4155\/fmc.09.71","article-title":"Therapeutic potential of boron containing compounds","volume":"1","author":"Baker","year":"2009","journal-title":"Future Med. Chem."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/S0960-894X(98)00029-8","article-title":"Potent, selective inhibitors of the proteasome: Dipeptidyl boronic acids","volume":"8","author":"Adams","year":"1998","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"5224","DOI":"10.1021\/cr500642d","article-title":"Recent developments in the chemistry and biological applications of benzoxaboroles","volume":"115","author":"Borys","year":"2015","journal-title":"Chem. Rev."},{"key":"ref_16","unstructured":"Anacor Pharmaceuticals (Press Release, 2014). FDA Approves Anacor Pharmaceuticals\u2019 KERYDIN\u00ae (Tavaborole) Topical Solution, 5% for the Treatment of Onychomycosis of the Toenails, Press Release."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1007\/s40257-017-0327-4","article-title":"Crisaborole ointment 2%: A review in mild to moderate atopic dermatitis","volume":"18","author":"Hoy","year":"2017","journal-title":"Am. J. Clin. Dermatol."},{"key":"ref_18","unstructured":"(2019). Scifinder, Version 2019, Chemical Abstracts Service."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1039\/C9MD00139E","article-title":"Recent development of leucyl-tRNA synthetase inhibitors as antimicrobial agents","volume":"10","author":"Zhang","year":"2019","journal-title":"Med. Chem. Commun."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1039\/C7MD00552K","article-title":"Synthesis of biologically active boron-containing compounds","volume":"9","author":"Yang","year":"2018","journal-title":"Med. Chem. Comm."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1021\/cr100093b","article-title":"Natural and Synthetic Small Boron-Containing Molecules as Potential Inhibitors of Bacterial and Fungal Quorum Sensing","volume":"111","author":"Dembitsky","year":"2011","journal-title":"Chem. Rev."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Silva, M.P., Saraiva, L., Pinto, M., and Sousa, M.E. (2020). Boronic Acids and Their Derivatives in Medicinal Chemistry: Synthesis and Biological Applications. Molecules, 25.","DOI":"10.3390\/molecules25184323"},{"key":"ref_23","unstructured":"(2021, February 11). Available online: https:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/336069\/9789240013131-eng.pdf."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1038\/nri3259","article-title":"The immunological life cycle of tuberculosis","volume":"12","author":"Ernst","year":"2012","journal-title":"Nat. Rev. Immunol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1038\/nrd.2018.28","article-title":"Accelerating the development of therapeutic strategies for drug-resistant tuberculosis","volume":"17","author":"Vjecha","year":"2018","journal-title":"Nat. Rev. Drug. Discov."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.bmcl.2016.11.084","article-title":"Recent advancements in the development of anti-tuberculosis drugs","volume":"27","author":"Chetty","year":"2017","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_27","first-page":"507","article-title":"Bromination of tolylboronic acids according to Wohl-Ziegler","volume":"10","author":"Torssell","year":"1957","journal-title":"Ark. Kemi."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"3533","DOI":"10.1016\/j.jorganchem.2009.07.022","article-title":"Benzoxaboroles\u2014Old compounds with new applications","volume":"694","author":"Cyranski","year":"2009","journal-title":"J. Organomet. Chem."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.jorganchem.2018.03.017","article-title":"Benzoboroxoles: Synthesis and applications in medicinal chemistry","volume":"865","author":"Mereddy","year":"2018","journal-title":"J. Organomet. Chem."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1080\/13543776.2018.1473379","article-title":"Benzoxaborole compounds for therapeutic uses: A patent review (2010\u20132018)","volume":"28","author":"Nocentini","year":"2018","journal-title":"Expert. Opin. Ther. Pat."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1007\/s11426-013-4981-y","article-title":"The synthesis of benzoxaboroles and their applications in medicinal chemistry","volume":"56","author":"Zhang","year":"2013","journal-title":"Sci. China Chem."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1126\/science.1142189","article-title":"An antifungal agent inhibits an aminoacyl-tRNA synthetase by trapping tRNA in the editing site","volume":"316","author":"Rock","year":"2007","journal-title":"Science"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1517\/14656566.2012.681779","article-title":"New therapeutic options for onychomycosis","volume":"13","author":"Gupta","year":"2012","journal-title":"Expert. Opin. Pharmacother."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"236","DOI":"10.4103\/0976-500X.171870","article-title":"An upcoming drug for onychomycosis: Tavaborole","volume":"6","author":"Sharma","year":"2015","journal-title":"J. Pharmacol. Pharmacother."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.bcp.2018.06.009","article-title":"Aminoacyl-tRNA synthetases, therapeutic targets for infectious diseases","volume":"154","author":"Lee","year":"2018","journal-title":"Biochem. Pharmacol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.jmb.2009.04.073","article-title":"Crystal structures of the human and fungal cytosolic Leucyl-tRNA synthetase editing domains: A structural basis for the rational design of antifungal benzoxaboroles","volume":"390","author":"Seiradake","year":"2009","journal-title":"J. Mol. Biol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"3795","DOI":"10.1016\/j.tet.2016.03.038","article-title":"Synthesis and evaluation of functionalized benzoboroxoles as potential anti-tuberculosis agents","volume":"72","author":"Alam","year":"2016","journal-title":"Tetrahedron"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"6271","DOI":"10.1128\/AAC.01339-16","article-title":"Discovery of Novel Oral Protein Synthesis Inhibitors of Mycobacterium Tuberculosis That Target Leucyl-tRNA Synthetase","volume":"60","author":"Palencia","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1042\/BJ20051249","article-title":"Crystal structures of the editing domain of Escherichia coli leucyl-tRNA synthetase and its complexes with Met and Ile reveal a lock-and-key mechanism for amino acid discrimination","volume":"394","author":"Liu","year":"2006","journal-title":"Biochem. J."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"8011","DOI":"10.1021\/acs.jmedchem.7b00631","article-title":"Discovery of a Potent and Specific M. tuberculosis Leucyl-tRNA Synthetase Inhibitor: (S)-3-(Aminomethyl)-4-chloro-7-(2-hydroxyethoxy)benzo[c][1,2]oxaborol-1(3H)-ol (GSK656)","volume":"60","author":"Li","year":"2017","journal-title":"J. Med. Chem."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1021\/acsmedchemlett.6b00300","article-title":"Characterization of the dynamic equilibrium between closed and open forms of the benzoxaborole pharmacophore","volume":"7","author":"Vshyvenko","year":"2016","journal-title":"ACS Med. Chem. Lett."},{"key":"ref_42","unstructured":"(2021, March 10). Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03075410."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"pii: e01205-17","DOI":"10.1128\/AAC.01205-17","article-title":"A Novel 6-Benzyl Ether Benzoxaborole Is Active against Mycobacterium tuberculosis in vitro","volume":"61","author":"Patel","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.tube.2017.11.003","article-title":"The 7-phenyl benzoxaborole series is active against Mycobacterium tuberculosis","volume":"108","author":"Korkegian","year":"2018","journal-title":"Tuberculosis"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1021\/bi4013897","article-title":"Mycobacterium tuberculosis type II NADH-menaquinone oxidoreductase catalyzes electron transfer through a two-site ping-pong mechanism and has two quinone-binding sites","volume":"53","author":"Yano","year":"2014","journal-title":"Biochemistry"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"2157","DOI":"10.1128\/AAC.45.7.2157-2159.2001","article-title":"Novel mutations in ndh in isoniazid-resistant Mycobacterium tuberculosis isolates","volume":"45","author":"Lee","year":"2001","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1111\/mmi.13120","article-title":"Type-II NADH:quinone oxidoreductase from Staphylococcus aureus has two distinct binding sites and is rate limited by quinone reduction","volume":"98","author":"Sena","year":"2015","journal-title":"Mol. Microbiol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"9524","DOI":"10.1039\/C9OB02222H","article-title":"Dimeric benzoboroxoles for targeted activity against Mycobacterium tuberculosis","volume":"17","author":"Guy","year":"2019","journal-title":"Org. Biomol. Chem."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"8619","DOI":"10.1021\/jm1009742","article-title":"Synthesis, in vitro and in vivo Biological Evaluation, and Comprehensive Understanding of Structure\u2014Activity Relationships of Dipeptidyl Boronic Acid Proteasome Inhibitors Constructed from \u03b2-Amino Acids","volume":"53","author":"Zhu","year":"2010","journal-title":"J. Med. Chem."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"4031","DOI":"10.1016\/j.bmc.2017.05.049","article-title":"Synthesis and biological activity of peptide proline-boronic acids as proteasome inhibitors","volume":"25","author":"Han","year":"2017","journal-title":"Bioorg. Med. Chem."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"239","DOI":"10.2174\/156800911794519752","article-title":"Bortezomib as the first proteasome inhibitor anticancer drug: Current status and future perspectives","volume":"11","author":"Chen","year":"2011","journal-title":"Curr. Cancer Drug Targets"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.str.2005.11.019","article-title":"Crystal structure of the boronic acid-based proteasome inhibitor bortezomib in complex with the yeast 20S proteasome","volume":"14","author":"Groll","year":"2006","journal-title":"Structure"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1038\/sj.leu.2404528","article-title":"Bortezomib-mediated 26S proteasome inhibition causes cell-cycle arrest and induces apoptosis in CD-30 anaplastic large cell lymphoma","volume":"21","author":"Bonvini","year":"2007","journal-title":"Leukemia"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"5311","DOI":"10.1158\/1078-0432.CCR-11-0476","article-title":"In vitro and in vivo selective antitumor activity of a novel orally bioavailable proteasome inhibitor MLN9708 against multiple myeloma cells","volume":"17","author":"Chauhan","year":"2011","journal-title":"Clin. Cancer. Res."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.ijmm.2013.09.001","article-title":"Bacterial caseinolytic proteases as novel targets for antibacterial treatment","volume":"304","author":"Sass","year":"2014","journal-title":"Int. J. Med. Microbiol."},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Raju, R.M., Jedrychowski, M.P., Wei, J., Pinkham, J.T., Park, A.S., O\u2019Brien, K., Rehren, G., Schnappinger, D., Gygi, S.P., and Rubin, E.J. (2014). Post-translational regulation via Clp protease is critical for survival of Mycobacterium tuberculosis. PLoS Pathog., 10.","DOI":"10.1371\/journal.ppat.1003994"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1146\/annurev.micro.62.081307.162948","article-title":"Biology of trans-translation","volume":"62","author":"Keiler","year":"2008","journal-title":"Annu. Rev. Microbiol."},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Raju, R.M., Unnikrishnan, M., Rubin, D.H., Krishnamoorthy, V., Kandror, O., Akopian, T.N., Goldberg, A.L., and Rubin, E.J. (2012). Mycobacterium tuberculosis ClpP1 and ClpP2 function together in protein degradation and are required for viability in vitro and during infection. PLoS Pathog., 8.","DOI":"10.1371\/journal.ppat.1002511"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"e00253-15","DOI":"10.1128\/mBio.00253-15","article-title":"Target mechanism-based whole-cell screening identifies bortezomib as an inhibitor of caseinolytic protease in mycobacteria","volume":"6","author":"Moreira","year":"2015","journal-title":"mBio"},{"key":"ref_60","first-page":"185","article-title":"Proteasome inhibitors: Complex tools for a complex enzyme","volume":"268","author":"Bogyo","year":"2002","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"746","DOI":"10.3389\/fmicb.2017.00746","article-title":"Bortezomib Warhead-Switch Confers Dual Activity against Mycobacterial Caseinolytic Protease and Proteasome and Selectivity against Human Proteasome","volume":"27","author":"Moreira","year":"2017","journal-title":"Front. Microbiol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"e02307-16","DOI":"10.1128\/AAC.02307-16","article-title":"Towards Selective Mycobacterial ClpP1P2 Inhibitors with Reduced Activity against the Human Proteasome","volume":"61","author":"Moreira","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0169-409X(96)00423-1","article-title":"Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings","volume":"23","author":"Lipinski","year":"1997","journal-title":"Adv. Drug. Deliv. Rev."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/j.ejmech.2019.06.092","article-title":"Boron in drug design: Recent advances in the development of new therapeutic agents","volume":"179","author":"Fernandes","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1021\/jm00374a003","article-title":"Preparation and antibacterial activities of new 1,2,3-diazaborine derivatives and analogs","volume":"27","author":"Grassberger","year":"1984","journal-title":"J. Med. Chem."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"2107","DOI":"10.1126\/science.274.5295.2107","article-title":"Mechanism of Drug Action Revealed by Structural Studies of Enoyl Reductase","volume":"274","author":"Baldock","year":"1996","journal-title":"Science"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1046\/j.1365-2958.1999.01182.x","article-title":"Molecular genetic analysis of enoyl-acyl carrier protein reductase inhibition by diazaborine","volume":"31","author":"Pielage","year":"1999","journal-title":"Mol. Microbiol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"e201800025","DOI":"10.26508\/lsa.201800025","article-title":"Discovery of a cofactor-independent inhibitor of Mycobacterium tuberculosis InhA","volume":"1","author":"Xia","year":"2018","journal-title":"Life Sci. Alliance"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1128\/CMR.18.1.81-101.2005","article-title":"Pathway to synthesis and processing of mycolic acids in Mycobacterium tuberculosis","volume":"18","author":"Takayama","year":"2005","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/S0960-894X(98)00126-7","article-title":"Syntheses and evaluation of benzodiazaborine compounds against M. tuberculosis H37Rv in vitro","volume":"8","author":"Davis","year":"1998","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1002\/cbdv.201400007","article-title":"Synthesis, Characterization, and Antibacterial Activity of Structurally Complex 2-Acylated 2,3,1-Benzodiazaborines and Related Compounds","volume":"11","author":"Kanichar","year":"2014","journal-title":"Chem. Biodivers."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"2415","DOI":"10.1002\/cbdv.200890206","article-title":"Synthesis, characterization, and antifungal activity of boron-containing thiosemicarbazones","volume":"5","author":"Hicks","year":"2008","journal-title":"Chem. Biodivers."},{"key":"ref_73","first-page":"201","article-title":"Preparation of Boron Containing Fungicides and Their Use in Compns. and Methods for the Control and\/or Prevention of Microbial Infection in Plants","volume":"9","author":"Rajan","year":"2018","journal-title":"MedChemComm"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"199","DOI":"10.3389\/fmicb.2016.00199","article-title":"Boromycin Kills Mycobacterial Persisters without Detectable Resistance","volume":"7","author":"Moreira","year":"2016","journal-title":"Front. Microbiol."},{"key":"ref_75","unstructured":"(2021, April 27). Available online: https:\/\/www.who.int\/publications\/i\/item\/9789240015791."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1051\/parasite\/2018021","article-title":"Plasmodium falciparum resistance to artemisinin-based combination therapies: A sword of Damocles in the path toward malaria elimination","volume":"25","author":"Ouji","year":"2018","journal-title":"Parasite"},{"key":"ref_77","unstructured":"(2021, February 10). Available online: https:\/\/www.cdc.gov\/malaria\/about\/biology\/index.html."},{"key":"ref_78","unstructured":"(2021, February 10). Artesunate. Available online: http:\/\/apps.who.int\/medicinedocs\/en\/d\/Jh2922e\/2.5.11.html."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1126\/science.aaa4102","article-title":"Understanding artemisinin resistance","volume":"347","author":"Sibley","year":"2015","journal-title":"Science"},{"key":"ref_80","doi-asserted-by":"crossref","unstructured":"Heller, L.E., and Roepe, P.D. (2019). Artemisinin-Based Antimalarial Drug Therapy: Molecular Pharmacology and Evolving Resistance. Trop. Med. Infect. Dis., 4.","DOI":"10.3390\/tropicalmed4020089"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1097\/QCO.0b013e32834c630e","article-title":"Boron-based drugs as antiprotozoals","volume":"24","author":"Jacobs","year":"2011","journal-title":"Curr. Opin. Infect. Dis."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1016\/j.bmcl.2010.12.034","article-title":"Synthesis and structure-activity relationships of novel benzoxaboroles as a new class of antimalarial agents","volume":"21","author":"Zhang","year":"2011","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"3909","DOI":"10.1016\/j.tetlet.2011.05.088","article-title":"An efficient synthesis for a new class antimalarial agent, 7-(2-carboxyethyl)-1,3-dihydro-1-hydroxy-2,1-benzoxaborole","volume":"52","author":"Zhang","year":"2011","journal-title":"Tetrahedron Lett."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1016\/j.bmcl.2011.12.096","article-title":"Benzoxaborole antimalarial agents. Part 2: Discovery of fluoro-substituted 7-(2-carboxyethyl)-1,3-dihydro-1-hydroxy-2,1-benzoxaboroles","volume":"22","author":"Zhang","year":"2012","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"5344","DOI":"10.1021\/acs.jmedchem.5b00678","article-title":"Benzoxaborole antimalarial agents. Part 4. Discovery of potent 6-(2-(alkoxycarbonyl)pyrazinyl-5-oxy)-1,3-dihydro-1-hydroxy-2,1-benzoxaboroles","volume":"58","author":"Zhang","year":"2015","journal-title":"J. Med. Chem."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"5889","DOI":"10.1021\/acs.jmedchem.7b00621","article-title":"Benzoxaborole Antimalarial Agents. Part 5. Lead Optimization of Novel Amide Pyrazinyloxy Benzoxaboroles and Identification of a Preclinical Candidate","volume":"60","author":"Zhang","year":"2017","journal-title":"J. Med. Chem."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"2475","DOI":"10.1038\/srep02475","article-title":"Discovery of a potent benzoxaborole-based anti-pneumococcal agent targeting leucyl-tRNA synthetase","volume":"3","author":"Hu","year":"2013","journal-title":"Sci. Rep."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"4886","DOI":"10.1128\/AAC.00820-16","article-title":"Antimalarial Benzoxaboroles Target Plasmodium falciparum Leucyl-tRNA Synthetase","volume":"60","author":"Sonoiki","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_89","unstructured":"Hernandez, V.S., Ding, C., Plattner, J.J., Alley, M.R.K., Rock, F., Zhang, S., Easom, E., Li, X., and Zhou, D. (2012). Benzoxaborole Derivatives for Treating Bacterial Infections. (WO2012033858A2)."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"14574","DOI":"10.1038\/ncomms14574","article-title":"A potent antimalarial benzoxaborole targets a Plasmodium falciparum cleavage and polyadenylation specificity factor homologue","volume":"8","author":"Sonoiki","year":"2017","journal-title":"Nat. Commun."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1038\/nature05363","article-title":"Polyadenylation factor CPSF-73 is the pre-mRNA 3\u2032-end-processing endonuclease","volume":"444","author":"Mandel","year":"2006","journal-title":"Nature"},{"key":"ref_92","unstructured":"(2021, April 28). The WHO List of 17 Neglected Tropical Diseases. Available online: https:\/\/www.who.int\/teams\/control-of-neglected-tropical-diseases\/overview\/progress-dashboard-2011-2020."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1186\/1756-3305-5-109","article-title":"The life cycle of Trypanosoma (Nannomonas) congolense in the tsetse fly","volume":"5","author":"Peacock","year":"2012","journal-title":"Parasites Vectors"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1021\/ml100013s","article-title":"Discovery of Novel Benzoxaborole-Based Potent Antitrypanosomal Agents","volume":"1","author":"Ding","year":"2010","journal-title":"ACS Med. Chem. Lett."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"4379","DOI":"10.1128\/AAC.00498-10","article-title":"Discovery of Novel Orally Bioavailable Oxaborole 6-Carboxamides That Demonstrate Cure in a Murine Model of Late-Stage Central Nervous System African Trypanosomiasis","volume":"54","author":"Nare","year":"2010","journal-title":"Antimicrobic. Agents Chemother."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1159\/000079137","article-title":"Steady-state brain concentrations of antihistamines in rats: Interplay of membrane permeability, P-glycoprotein efflux and plasma protein binding","volume":"72","author":"Doan","year":"2004","journal-title":"Pharmacology"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.4155\/fmc.11.80","article-title":"Benzoxaboroles: A new class of potential drugs for human African trypanosomiasis","volume":"3","author":"Jacobs","year":"2011","journal-title":"Future Med. Chem."},{"key":"ref_98","doi-asserted-by":"crossref","unstructured":"Jacobs, R.T., Nare, B., Wring, S.A., Orr, M.D., Chen, D., Sligar, J.M., Jenks, M.X., Noe, R.A., Bowling, T.S., and Mercer, L.T. (2011). SCYX-7158, an orally-active benzoxaborole for the treatment of stage 2 human African trypanosomiasis. PLoS Negl. Trop. Dis., 5.","DOI":"10.1371\/journal.pntd.0001151"},{"key":"ref_99","unstructured":"(2021, March 11). Drugs for Neglected Diseases Initiative (Dndi). Dndi Announces Successful Completion of SCYX-7158 Phase I Study for Treatment of Sleeping Sicknes. Available online: https:\/\/www.news-medical.net\/news\/20150909\/DNDi-announces-successful-completion-of-SCYX-7158-Phase-I-study-for-treatment-of-sleeping-sickness.aspx."},{"key":"ref_100","unstructured":"(2021, April 20). Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03087955."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"6230","DOI":"10.1021\/jm800812k","article-title":"Synthesis, cytotoxicity, and anti-Trypanosoma cruzi activity of new chalcones","volume":"51","author":"Aponte","year":"2008","journal-title":"J. Med. Chem."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"3553","DOI":"10.1021\/jm2012408","article-title":"Chalcone\u2013Benzoxaborole Hybrid Molecules as Potent Antitrypanosomal Agents","volume":"55","author":"Qiao","year":"2012","journal-title":"J. Med. Chem."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.ejmech.2014.04.079","article-title":"Novel pyrrolobenzoxaboroles: Design, synthesis, and biological evaluation against Trypanosoma brucei","volume":"81","author":"Wu","year":"2014","journal-title":"Eur. J. Med. Chem."},{"key":"ref_104","doi-asserted-by":"crossref","unstructured":"Gumbo, M., Beteck, R.M., Mandizvo, T., Seldon, R., Warner, D.F., Hoppe, H.C., Isaacs, M., Laming, D., Tam, C.C., and Cheng, L.W. (2018). Cinnamoyl-Oxaborole Amides: Synthesis and Their in Vitro Biological Activity. Molecules., 23.","DOI":"10.3390\/molecules23082038"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1021\/jm101225g","article-title":"Design, synthesis, and structure-activity relationship of Trypanosoma brucei leucyl-tRNA synthetase inhibitors as antitrypanosomal agents","volume":"54","author":"Ding","year":"2011","journal-title":"J. Med. Chem."},{"key":"ref_106","unstructured":"(2021, April 29). Available online: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/leishmaniasis."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"750","DOI":"10.12688\/f1000research.11120.1","article-title":"Leishmaniasis: A review","volume":"6","author":"Arenas","year":"2017","journal-title":"F1000Res."},{"key":"ref_108","doi-asserted-by":"crossref","unstructured":"Sundar, S., Pandey, K., Thakur, C.P., Jha, T.K., Das, V.N.R., Verma, N., Lal, C.S., Verma, D., Alam, S., and Das, P. (2014). Efficacy and safety of amphotericin B emulsion versus liposomal formulation in Indian patients with visceral leishmaniasis: A randomized, open-label study. PLoS Negl. Trop. Dis., 8.","DOI":"10.1371\/journal.pntd.0003169"},{"key":"ref_109","first-page":"26","article-title":"Limitations of current therapeutic options, possible drug targets and scope of natural products in control of leishmaniasis","volume":"18","author":"Tiwari","year":"2018","journal-title":"Mini. Rev. Med. Chem."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"580","DOI":"10.4269\/ajtmh.2009.80.580","article-title":"Relapse of visceral leishmaniasis after miltefosine treatment in a Nepalese patient","volume":"80","author":"Pandey","year":"2009","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"ref_111","unstructured":"(2021, February 22). Accelerating work to overcome the global impact of neglected tropical diseases: A roadmap for implementation. WHO\/HTM\/NTD\/2012. World Health Organization, Geneva, Switzerland. Available online: http:\/\/www.who.int\/neglected_diseases\/NTD_RoadMap_2012_Fullversion.pdf."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"e00079-18","DOI":"10.1128\/AAC.00079-18","article-title":"Leishmania donovani Parasites Are Inhibited by the Benzoxaborole AN2690 Targeting Leucyl-tRNA Synthetase","volume":"62","author":"Manhas","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1016\/j.bmc.2017.01.034","article-title":"Carbonic anhydrases from Trypanosoma and Leishmania as anti-protozoan drug targets","volume":"25","author":"Vermelho","year":"2017","journal-title":"Bioorg. Med. Chem."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1517\/14728222.2015.1067685","article-title":"Bacterial, fungal and protozoan carbonic anhydrases as drug targets","volume":"19","author":"Capasso","year":"2015","journal-title":"Expert Opin. Ther. Targets"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1080\/14756366.2017.1414808","article-title":"Carbonic anhydrases from Trypanosoma cruzi and Leishmania donovani chagasi are inhibited by benzoxaboroles","volume":"33","author":"Nocentini","year":"2018","journal-title":"Enzyme Inhib. Med. Chem."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"e02419-17","DOI":"10.1128\/AAC.02419-17","article-title":"Topical Treatment for Cutaneous Leishmaniasis: Dermato-Pharmacokinetic Lead Optimization of Benzoxaboroles","volume":"62","author":"Gaukel","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_117","unstructured":"(2021, April 21). Available online: https:\/\/www.who.int\/blindness\/partnerships\/onchocerciasis_disease_information\/en\/."},{"key":"ref_118","unstructured":"(2021, April 21). Available online: https:\/\/www.who.int\/lymphatic_filariasis\/en\/."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1073\/pnas.38.7.555","article-title":"Antibiotic substances from basidiomycetes: IX. Drosophila subtarata. (batsch ex fr.) quel","volume":"38","author":"Kavanagh","year":"1952","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1111\/j.1365-2958.2004.04346.x","article-title":"Inhibition of peptide bond formation by pleuromutilins: The structure of the 50S ribosomal subunit from Deinococcus radiodurans in complex with tiamulin","volume":"54","author":"Schlunzen","year":"2004","journal-title":"Mol. Microbiol."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1021\/acs.jmedchem.8b01854","article-title":"Boron-Pleuromutilins as Anti-Wolbachia Agents with Potential for Treatment of Onchocerciasis and Lymphatic Filariasis","volume":"62","author":"Jacobs","year":"2019","journal-title":"J. Med. Chem."},{"key":"ref_122","unstructured":"Zhang, Y.-K., Zhou, H., Ding, C., Plattner, J.J., and Freund, Y. (2011). Boron-Containing Small Molecules as Antihelminth Agents. (WO201106)."},{"key":"ref_123","unstructured":"(2021, April 29). Available online: https:\/\/en.wikipedia.org\/wiki\/Cryptosporidiosis."},{"key":"ref_124","unstructured":"(2021, March 01). WHO. World Health Organization. Available online: https:\/\/www.who.int\/water_sanitation_health\/gdwqrevision\/cryptodraft2.pdf."},{"key":"ref_125","doi-asserted-by":"crossref","unstructured":"Weiss, L.M. (2014). Chapter 1\u2014The History and Life Cycle of Toxoplasma Gondii in Toxoplasma Gondii, Academic Press. [2nd ed.].","DOI":"10.1016\/B978-0-12-396481-6.00001-5"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"3550","DOI":"10.2174\/092986712801323199","article-title":"Aminoacyl-tRNA synthetase inhibitors as potent antibacterials","volume":"19","author":"Lv","year":"2012","journal-title":"Curr. Med. Chem."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"5817","DOI":"10.1128\/AAC.00873-16","article-title":"Cryptosporidium and Toxoplasma Parasites Are Inhibited by a Benzoxaborole Targeting Leucyl-tRNA Synthetase","volume":"60","author":"Palencia","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1038\/s41564-020-0768-z","article-title":"Research funding after COVID-19","volume":"5","author":"Costa","year":"2020","journal-title":"Nat. Microbiol."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"E6","DOI":"10.1016\/S1470-2045(20)30749-X","article-title":"Cuts in cancer research funding due to COVID-19","volume":"22","author":"Burki","year":"2021","journal-title":"Lancet Oncol."}],"container-title":["Molecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1420-3049\/26\/11\/3309\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T06:09:30Z","timestamp":1760162970000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1420-3049\/26\/11\/3309"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,31]]},"references-count":129,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2021,6]]}},"alternative-id":["molecules26113309"],"URL":"https:\/\/doi.org\/10.3390\/molecules26113309","relation":{},"ISSN":["1420-3049"],"issn-type":[{"value":"1420-3049","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,31]]}}}